Dr. Cercek on the Need for Treatment Options in KRAS-Mutated mCRC

Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the need for treatment options in KRAS-mutated metastatic colorectal cancer (mCRC).

KRAS mutations comprise about 50% of patients with mCRC. Patients with a KRAS mutation have 1 less therapeutic option because they cannot be treated with anti-EGFR therapy, said Cercek. There have been poor responses in the mCRC setting of KRAS-mutated tumors with certain treatments, such as cetuximab (Erbitux) and panitumumab (Vectibix).

Emerging studies will focus on helping this particular patient population, concludes Cercek.